SLC22A3 and myelodysplastic syndrome: As shown in Fig. 2C, SLC22A3 methylation pattern was markedly higher in whole-cohort AML samples than in control and MDS groups (P < 0.001 and = 0.002), as well as in non-APL AML (n = 107) and CN AML (n = 58) vs. controls, respectively (P < 0.001 and = 0.002).